MP15-20 NEO-ADJUVANT 177Lu-PSMA-I&T RADIONUCLIDE IN HIGH-RISK PROSTATE CANCER BEFORE RADICAL PROSTATECTOMY: A FEASIBILITY TRIAL

You have accessJournal of UrologyProstate Cancer: Localized: Surgical Therapy I (MP15)1 Sep 2021MP15-20 NEO-ADJUVANT 177Lu-PSMA-I&T RADIONUCLIDE IN HIGH-RISK PROSTATE CANCER BEFORE RADICAL PROSTATECTOMY: A FEASIBILITY TRIAL Michael Frumer, Eli Rosenbaum, Daniel Kedar, Yarden Zohar, Jack Baniel, Adam Steinmetz, Hanna Bernstine, David Groshar, and Shay Golan Michael FrumerMichael Frumer More articles by this author , Eli RosenbaumEli Rosenbaum More articles by this author , Daniel KedarDaniel Kedar More articles by this author , Yarden ZoharYarden Zohar More articles by this author , Jack BanielJack Baniel More articles by this author , Adam SteinmetzAdam Steinmetz More articles by this author , Hanna BernstineHanna Bernstine More articles by this author , David GrosharDavid Groshar More articles by this author , and Shay GolanShay Golan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001996.20AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: We report preliminary results of an open-label, single-arm clinical trial evaluating the safety and immediate oncological outcomes of 177Lu-PSMA-I&T (LuPSMA), followed by radical prostatectomy (RP) with pelvic lymph node dissection (PLND) in patients with high-risk prostate cancer (HRPCa). METHODS: Consecutive HRPCa patients with high PSMA avidity on 68Ga- PSMA PET/CT received two 7.4 GBq LuPSMA treatments 6 and 8 weeks before RP with PLND. LuPSMA side effects and surgical parameters were documented. Final surgical pathology and postoperative biochemical response were recorded. All patients completed validated health-related quality of life questionnaires at baseline and during postoperative follow-up. RESULTS: Seven patients with HRPCa were treated with two LuPSMA treatments, and as of this writing, six of them were operated on. The median age was 66 years (IQR 60, 68) and the median baseline PSA was 11.4 ng/dL (IQR 7.6, 27). Four patients were Gleason grade group 4 and three were Gleason grade group 5. The only reported adverse event during LuPSMA treatment was fatigue in 1 patient (14%). In 2 out of 6 operated patients, periprostatic adhesions were encountered during surgery without any intraoperative complications. The median surgical length and median estimated blood loss was 240 minutes (IQR 200, 260) and 250 ml (IQR 200, 350), respectively. The only postoperative event was fever in 1 patient (14%). The median hospital stay was 3 days (IQR 2, 4). Treatment-related histological changes were noted in 4 of 6 final surgical specimens. Positive surgical margins were identified in 2 patients. Biochemical response was observed in all patients, with a median postoperative PSA of 0.01 ng/dL (IQR 0.01, 0.07). All 6 patients required ≤1 pad at 3 months after surgery. CONCLUSIONS: Preliminary data suggest that two LuPSMA treatments followed by RP can be safely applied to patients with locally advanced HRPCa. While longer oncological outcomes are pending, continence recovery seems to be unaffected by LuPSMA treatment. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e271-e271 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Michael Frumer More articles by this author Eli Rosenbaum More articles by this author Daniel Kedar More articles by this author Yarden Zohar More articles by this author Jack Baniel More articles by this author Adam Steinmetz More articles by this author Hanna Bernstine More articles by this author David Groshar More articles by this author Shay Golan More articles by this author Expand All Advertisement Loading ...